The U.S. Food and Drug Administration just handed Viridian Therapeutics a big win. On Friday, the agency approved the company's new thyroid eye disease (TED) treatment, Lumvoa (veligrotug-vvze), marking Viridian's first-ever approved therapy and setting up a direct challenge to Amgen's Tepezza.

For anyone unfamiliar, thyroid eye disease is a rare autoimmune condition that causes the tissues around your eyes to become inflamed and remodel themselves — not a pleasant experience. It can lead to bulging eyes, double vision, and in severe cases, vision loss. Until now, Amgen's Tepezza has been the go-to treatment, but Viridian is hoping its new drug can carve out a serious chunk of that market.

The approval is a huge milestone for Viridian, which is now transitioning from a development-stage biotech to a commercial-stage company. And they're not wasting any time: the company says it's launching Lumvoa immediately, with a comprehensive patient support program to help folks navigate insurance and access the drug.

What Makes Lumvoa Different?

The FDA granted Lumvoa Priority Review based on data from two pivotal Phase 3 trials: THRIVE, which looked at patients with active TED, and THRIVE-2, which focused on patients with the chronic form of the disease. Both trials hit all their primary and secondary endpoints, showing statistically significant and clinically meaningful improvements by week 15.

Lumvoa works as a full antagonist of IGF-1R, and it's the first approved TED therapy to include official labeling data for both active and chronic forms. That's a big deal because it means the drug could be used across a broader patient population than Tepezza, which is primarily approved for active disease.

The treatment regimen is designed to minimize burden: patients receive a 12-week course of subcutaneous injections. And the benefits kick in fast — patients saw reductions in proptosis (that's the medical term for bulging eyes) as early as three weeks. Lumvoa is also the first approved TED drug to show a statistically significant impact on double vision (diplopia) response, with complete resolution in both active and chronic patients.

Analyst Take: Tepezza, Watch Your Back

William Blair analyst Lachlan Hanbury-Brown is bullish on Lumvoa's chances. In a note Monday, he wrote: "We believe Lumvoa has the potential to capture meaningful market share from Amgen's Tepezza, supported by its competitive clinical profile across both active and chronic TED populations, with potential for modest market expansion."

He also highlighted that Viridian's other candidate, elegrobart, remains on track for a BLA filing in the first quarter of 2027 and is well-positioned to expand into the chronic patient population. Combined with Viridian's broader portfolio, elegrobart could help the company target multiple patient segments and strengthen its long-term position in the TED market.

Hanbury-Brown added that Lumvoa could emerge as a leading option for chronic TED patients, thanks to its convenient subcutaneous administration and strong clinical profile.

Market Reaction

Investors are clearly excited. Viridian Therapeutics shares were up 13.79% at $20.36 in premarket trading on Monday, according to market data. The stock has been on a rollercoaster this year, but this approval could be the catalyst that changes the trajectory.

For Amgen, the threat is real. Tepezza has been a blockbuster, but competition is finally arriving. Viridian's drug offers a compelling alternative, and with a rapid launch and strong data, it could quickly become the new standard of care for thyroid eye disease.